about
Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron lossVPAC receptors: structure, molecular pharmacology and interaction with accessory proteinsNeurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutationNuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptideSubcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice.NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)Neuroprotection in experimental stroke with targeted neurotrophins.The unfolding story of the chaperonins.Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathwaysDeath and survival of neuronal cells exposed to Alzheimer's insults.Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicityTargeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Neuroprotective peptide ADNF-9 in fetal brain of C57BL/6 mice exposed prenatally to alcoholActivity-dependent neurotrophic factor-derived peptide prevents alcohol-induced apoptosis, in part, through Bcl2 and c-Jun N-terminal kinase signaling pathways in fetal brain of C57BL/6 mouseActivity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse.Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug designNeurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse.Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.Cerebral cortical astroglia from the trisomy 16 mouse, a model for down syndrome, produce neuronal cholinergic deficits in cell culture.Experimental methods for testing the effects of neurotrophic peptide, ADNF-9, against alcohol-induced apoptosis during pregnancy in c57bl/6 miceNeurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's diseaseDose-response features of neuroprotective agents: an integrative summary.Pharmacological enhancement of neuronal survival.VIP down-regulates the inflammatory potential and promotes survival of dying (neural crest-derived) corneal endothelial cells ex vivo: necrosis to apoptosis switch and up-regulation of Bcl-2 and N-cadherinInhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brainA novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL/6 mice: signaling pathway investigations.Microtubule stabilising peptides rescue tau phenotypes in-vivo.Targeting neuroinflammation for therapeutic intervention in neurodegenerative pathologies: a role for the peptide analogue of thymulin (PAT).D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.NAP reduces murine microvascular endothelial cells proliferation induced by hyperglycemia.The effects of vasoactive intestinal peptide in neurodegenerative disorders.Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats.
P2860
Q22337080-5B771752-8290-4127-8D0E-F20B6CA47B05Q26827172-4ACFDBD6-1F2C-43A3-812B-4CCD4EE0ABFAQ28506810-18655BD5-41AF-4507-B8C0-2006B3D14578Q28570882-E7E986B3-03BC-4BB7-A36C-E15B67CD61ADQ28592586-884CC182-9628-429B-8B9F-E8968AE12A71Q29347042-9A5EEDD5-C862-4B53-924D-46627EF53A88Q30489888-88D69BA3-B6AC-48BD-82F4-B13DF540D26CQ33393912-1A8C8F8D-411D-467F-8CD1-35204BDEE430Q33569623-D5AF5D63-2A66-4571-A9DB-7EEDD7E4BD4AQ33923440-173034C1-9F88-4B05-8ECC-353A5B14BA74Q34064026-8DE512C6-DA58-4A0A-8A83-96AE17CD5D0EQ34542229-602CA5F0-3124-43C6-A5F3-AB23B076F4BDQ34581033-342D5EFD-1F13-4602-AFBF-F5A92192AA92Q34976286-FFC5EEAE-A625-436B-9A2C-658704FE362DQ35168601-DEA52E2D-88DF-4F46-BB50-7CEDADF23FD7Q35295564-C1FBA10B-6476-45C6-B755-8E75BD77852EQ35548667-E5D1B1DD-30A8-45F2-9C5B-980E0D97AEA0Q35714100-0CA817EA-B76E-4C38-ADBC-61B43981B8F7Q36422348-3F9AA1E7-2129-4045-A3E6-850ECECB7417Q36460261-31579D94-963C-4CA9-B1D9-6594E3E494E3Q36501608-4B2FEDC9-2491-4AC1-8D00-5A11D6A57C06Q36734495-08C36CCC-91BD-4130-9D86-123A3A406530Q36827809-F8FF21C4-3D7E-41A7-A604-F3D95C142FBEQ36886815-0243BB40-E5D1-4688-B929-5C497F9C513BQ36940103-65E0294F-3A4E-4A8A-978E-C404A837C16CQ37146134-D36334B1-8ACE-4A31-BEC8-DD3178BB67CAQ37146138-1455262C-A1DA-4476-A174-EA42F48CCFA0Q37242900-D5FC75D5-BD8A-4E75-8DB5-A832ABB86FDCQ37368552-A41ED740-CF4B-44B7-8486-BEE0427CFA7FQ37370085-EF5A8833-F729-4F1E-8998-7A6722496AC7Q37441352-235D3A9A-1066-4DB6-B881-555A00F78F8FQ37464820-039CD5C5-5EE1-4EB4-A12D-5D037F5246D4Q38031912-EF9299DD-5395-4BD1-AC04-200E4178427CQ38041481-2670BAD5-B53B-4AFB-8F55-ED1C336EAAF5Q38286222-C3821B06-2D83-4012-9E65-2E38C4550F11Q38792682-C85AF87A-C3A2-4BED-9376-C01AAC4E2EC0Q38990446-9527A619-A23A-4F29-86ED-006A747B1172Q38992271-39FD3854-9751-4760-B408-8C631EB395E1Q39008879-A198B7FA-6494-41D9-93A4-69CA3037D1DBQ39137563-E0078A6D-0307-49C4-83D5-5CFACC35D0C3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A femtomolar-acting neuroprotective peptide
@en
A femtomolar-acting neuroprotective peptide.
@nl
type
label
A femtomolar-acting neuroprotective peptide
@en
A femtomolar-acting neuroprotective peptide.
@nl
prefLabel
A femtomolar-acting neuroprotective peptide
@en
A femtomolar-acting neuroprotective peptide.
@nl
P2860
P356
P1476
A femtomolar-acting neuroprotective peptide
@en
P2093
P2860
P304
P356
10.1172/JCI118672
P407
P577
1996-05-01T00:00:00Z